S02:5 | Combined anti-IL-5/IL-5r and dupilumab therapy in eosinophilic granulomatosis with polyangiitis: a European retrospective study

Miriam Guerini¹, Pavel Novikov², Roberto Padoan³, Georgina Espigol Frigolé⁴, Jan Willem Cohen Tervaert⁵, Vincent Grobost⁶, Laurent Guilleminault⁷, Jan Walter Schroeder⁸, Bernhard Hellmich⁹, Joana Martins Martinho¹⁰, Camillo Ribi¹¹, Matthieu Groh¹², Benjamin Terrier¹³. | ¹IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy; ²Sechenov University, Moscow, Russia; ³University of Padova, Padova, Italy; ⁴Hospital Clinic, University of Barcelona, Barcelona, Spain; ⁵University of Alberta, Edmonton, Canada; ⁶CHU Estaing Clermont-Ferrand France; ⁷Toulouse University Toulouse France; ⁸ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; ⁹Medius Kliniken Kirchheim-Teck Germany; ¹⁰ULS Santa Maria, Lisbon, Portugal; ¹¹Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; ¹²Hopital Foch, Suresnes, France; ¹³Service de Medecine interne, Hopital Cochin, AP-HP, Paris, France.

Background. Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, ear, nose, and throat (ENT) symptoms, eosinophilia, and systemic involvement. Despite the use of anti-interleukin (IL)-5/IL-5R therapies, asthma or primarily ENT symptoms may persist. Dupilumab (anti-IL-4R) is approved for severe asthma and chronic rhinosinusitis but has been associated with drug-induced eosinophilia and EGPA flares. Given their complementary mechanisms, the combination of anti-IL-5/IL-5R and dupilumab may improve disease control in patients with EGPA. We report the safety and efficacy of this off-label combination in relapsing/refractory EGPA.

Materials and Methods. This European, multicenter, retrospective study included EGPA patients fulfilling 2022 ACR/EULAR classification criteria treated with anti-IL-5/IL-5R in combination with dupilumab for relapsed or refractory disease. Complete response (CR) was defined as BVAS=0 and prednisone dose (PDN) not exceeding 4 mg/day, partial response (PR) as BVAS=0 and PDN >4 mg/day. Failure was defined as inability to reduce PDN <7.5 mg/day due to persistently active disease, vasculitis relapse and/or worsening of asthma or ENT symptoms requiring treatment escalation.

Results. Sixteen patients received the combination therapy, with mepolizumab or benralizumab in 8 cases each. Twelve patients (75%) received the addition of dupilumab to ongoing anti-IL-5/IL-5R, 6 for uncontrolled ENT symptoms, 5 for both uncontrolled ENT and asthma symptoms, and 1 for uncontrolled asthma. The remaining 4 patients (25%) received the addition of anti-IL-5/IL-5R to dupilumab for drug-induced eosinophilia associated with vasculitis relapse in 3 patients and for uncontrolled ENT symptoms/asthma in 3 cases. Thirteen patients [Figure 1] with at least 3 months of follow-up were analyzed for efficacy (median follow-up 6 (3-12) months). At the start of combination therapy, the median PDN dose was 5 mg/day (0-10), decreasing to 4.38 mg/day (0-6.25) at 3 months and 3.75 mg/day (1.25-5) at 6 months. In patients with dupilumab-induced eosinophilia, the addition of anti-IL-5/IL-5R reduced eosinophil counts from 1600/uL (1082-4000) to 170/uL (90-465) at 3 months and remained 170/uL (165-175) at 6 months. No eosinophilia occurred when dupilumab was added to anti-IL-5/IL-5R. At 3 months, 4/13 (31%) and 1/13 (8%) achieved CR and PR, respectively, while 3/13 (23%) had treatment failure. At 6 months (data available for 11 patients), 5/11 (45%) and 3/11 (27%) achieved CR and PR, respectively, and at 9 months, CR was achieved in all patients with available follow-up, except for the 3 patients with initial treatment failure [Figure 2]. Safety analysis showed no serious adverse events, only two patients reported mild-to-moderate adverse events.

Conclusions. The combination of anti-IL-5/IL-5R and dupilumab in this case series was safe and appeared to be an effective option in EGPA patients with uncontrolled ENT manifestations while on anti-IL-5/IL-5R or in patients with dupilumab-induced hypereosinophilia and EGPA manifestations, with optimal response requiring at least 6 months of treatment.